CNBC's David Faber breaks down the latest details about a bidding war between Pfizer and Novo Nordisk for Metsera.
Breakdown
- A bidding war has emerged between Pfizer and Novo Nordisk for control of Metsera.
- Novo Nordisk countered Pfizer's initial offer with a structure providing immediate payment to Metsera shareholders, leading Pfizer to file a lawsuit and raise its own bid. 15s
- Novo Nordisk's latest offer totals $86.20 per share, including a $24 contingent value right, and has been deemed superior to Pfizer's bid. 1m 2s
- Pfizer has four days to respond to Novo's superior bid, while a court considers Pfizer's request for a temporary restraining order against Novo's offer structure. 1m 25s
- Pfizer CEO Albert Bourla argued that Novo Nordisk's offer faces significant antitrust risks and may not be completed. 2m 7s